Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate whether or not cerebral atrophy scores obtained from a brain MRI can correlate with Cognitive Test results. These results hope to demonstrate a link between cerebral ischemic/degenerative changes shown on the MRI and cognition functions results.
| Condition |
|---|
|
Cognitive Decline |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition |
- Correlate quantitative measures of cerebral atrophic and ischemic changes with level of cognition using Mental Status Exam and Brain MRI exam [ Time Frame: One time visit, duration of MRI ] [ Designated as safety issue: No ]
- Establish reliable imaging criteria to identify normal age induced changes versus pathologic process comparing Mental Status Exam with Brain MRI(measuring CSF and Brain volumes) [ Time Frame: Duration of study 3 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2008 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Preliminary evidence indicates that intracranial atherosclerosis may predict incident cerebrovascular events and central atrophy. Age induced changes on cerebral tissue in adulthood is witnessed as atrophy and well know ischemic changes on imaging studies. There is no consensus at this time what constitutes normal, age induced atrophy and pathologic atrophy on imaging studies. The same challenge is also encountered for ischemic cerebral parenchymal change.
Until recently there have been several important limitations in this research 1) Measurement of cerebral tissue loss and amount of ischemic insult was based on a qualitative grading (2) There was no cognitive testing. With Advancements in software technology that have now allowed for measurements of CSF and brain volumes in reliable and reproducible ways and the neuroradiologist having access to the subject's Neurological Cognitive Testing Scores, this study will objectively measure MRI findings and correlate them with the level of cognitive function.
This study will look at subjects who have undergone cognitive testing from the Neurology Clinic and then referred for an MRI brain exam, as standard of care testing. The MRI information will be acquired by volumetric technique for calculation of brain and CSF volumes and MRI data will be plotted against the cognitive test results.
The results of this study will be to correlate quantitative measures of cerebral atrophic and ischemic changes with level of cognition and to establish reliable imaging criteria that can help identify normal, age induced versus pathologic. Information obtained will shed light to cognitive effects and imaging appearance of: Separation of normal age related changes from pathologic states, changes leading to dementia and normal pressure hydrocephalus.
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects identified from Neurology Department who have already undergone Cognitive Testing and have been referred for an MRI exam
Inclusion Criteria:
- Subjects older than 50 years of age
- Subjects who have undergone Cognitive Testing
- Subjects who can cooperate and give informed consent
Exclusion Criteria:
- Subjects with known medical conditions predisposing them for atrophy such as: Chronic renal failure, HIV, head/neck tumors, prior radiation, post- traumatic brain disorder, metabolic disorders of brain, polysubstance abuse, and steroid use
Contacts and Locations| Contact: Sami H. Erbay, M.D. | 781-744-8170 | Sami.Erbay@Lahey.org |
| United States, Massachusetts | |
| Lahey Clinic, Inc. | Recruiting |
| Burlington, Massachusetts, United States, 01805 | |
| Contact: Sami H. Erbay, M.D. 781-744-8170 Sami.Erbay@Lahey.org | |
| Sub-Investigator: Grace M. Lee, M.D. | |
| Sub-Investigator: Yuval Zabar, M.D. | |
| Sub-Investigator: Karen Hanley | |
| Principal Investigator: | Sami H. Erbay, M.D. | Lahey Clinic, Inc. |
More Information
Publications:
| Responsible Party: | Lahey Clinic |
| ClinicalTrials.gov Identifier: | NCT00704327 History of Changes |
| Other Study ID Numbers: | 2008-029 |
| Study First Received: | June 20, 2008 |
| Last Updated: | May 7, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Lahey Clinic:
|
Cognitive Functions Brain Ischemia Cerebral Atrophy |
Dementia Intracranial atherosclerosis Memory impairment |
Additional relevant MeSH terms:
|
Cognition Disorders Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 22, 2013